EGFR and non-small cell lung carcinoma: According to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for NSCLC [6], the preferred first-line option for EGFR-mutant NSCLC is osimertinib, a third-generation EGFR TKI.